Search

Displaying results 4631 - 4640 of 10000 in total
  1. Drug

    Imidafenacin

    go.drugbank.com/drugs/DB09262
    Investigational

    Imidafenacin is an antispasmodic agent with anticholinergic effects. It antagonizes muscarinic receptors in the bladder to reduce the frequency of urination in the treatment of overactive bladder. … It is marketed in Japan under the tradenames Staybla by Ono Pharmaceutical and Uritos by Kyojin Pharmaceutical.

    Categories: Drugs for Urinary Frequency and Incontinence
  2. Drug

    AVI-5126

    go.drugbank.com/drugs/DB05726
    Investigational

    AVI-526 is an improved formulation of [AVI-4557], developed for use on Vein Grafts before use in Heart by-Pass Graft Surgery. … AVI-526 works by silencing a gene known as c-myc, a key regulatory gene involved in cardiovascular restenosis.

  3. Drug

    Darapladib

    go.drugbank.com/drugs/DB06311
    Investigational

  4. Drug

    Morniflumate

    go.drugbank.com/drugs/DB09285
    Investigational

    Morniflumate is a non-steroidal anti-inflammatory drug with antipyretic properties. It is the morpholinoethyl ester of niflumic acid [L1496]. … In one study, post morniflumate ingestion, physical examination and clinical symptoms of those with bronchitis showed improvement [A7889].

  5. Drug

    CCR5 mAb

    go.drugbank.com/drugs/DB05906
    Experimental

    CCR5 mAb is a fully human monoclonal antibody that specifically recognizes and binds the chemokine receptor CCR5, which is known to be a key facilitator of infection with human immunodeficiency virus (

  6. Drug

    Icalcaprant

    go.drugbank.com/drugs/DB21651
    Investigational

    Icalcaprant is a small molecule drug. The usage of the INN stem '-caprant' in the name indicates that Icalcaprant is a kappa-opioid receptor (KOR) antagonist. … Icalcaprant is under investigation in clinical trial NCT06696755 (A Study to Assess Adverse Events and Change in Disease Activity of Oral Icalcaprant in Adult Participants With Bipolar I or II Disorder

  7. Drug

    Amobarbital

    go.drugbank.com/drugs/DB01351
    ApprovedIllicit

    Adverse effects are mainly a consequence of dose-related CNS depression and the risk of dependence with continued use is high. (From Martindale, The Extra Pharmacopoeia, 30th ed, p565) … A barbiturate with hypnotic and sedative properties (but not antianxiety).

  8. Drug

    ZD4407

    go.drugbank.com/drugs/DB06539
    Experimental

    The drug ZD4407, an antiasthmatic developed by AstraZeneca, functions as a 5-lipoxygenase inhibitor. … It entered Phase 1 clinical trials for chronic obstructive pulmonary disease (COPD) in the United Kingdom but was discontinued during this phase in March 2003

  9. Drug

    GEM-231

    go.drugbank.com/drugs/DB05798
    Investigational

    A monoclonal antibody combined with a toxic substance that is used treat certain types of acute myeloid leukemia in older patients and is being studied in the treatment of other types of cancer. … Monoclonal antibodies are made in the laboratory and can locate and bind to cancer cells.

  10. Drug

    ORG-34517

    go.drugbank.com/drugs/DB05423
    Investigational

    It has potential to treat a number of diseases such as Cushing’s disease, hypertension, diabetes, glaucoma etc, in which the activity of metabolites corticosterone and cortisol is high. … ORG-34517 is currently under investigation by Organon for the treatment of depression.